ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy

European Urology

Volumn 69, Issue 3, 2016, Pages 384-388

  Groenendijk, Floris H ^a   De Jong, Jeroen ^a   Fransen Van De Putte, Elisabeth E ^a   Michaut, Magali ^a   Schlicker, Andreas ^a   Peters, Dennis ^a   Velds, Arno ^a   Nieuwland, Marja ^a   Van Den Heuvel, Michel M ^a   Kerkhoven, Ron M ^a   Wessels, Lodewijk F ^a   Broeks, Annegien ^a   Van Rhijn, Bas W G ^a   Bernards, René ^a   Van Der Heijden, Michiel S ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

ERBB2; ERCC2; Muscle invasive bladder cancer; Neoadjuvant chemotherapy; Response

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; METHOTREXATE; VINBLASTINE; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER ADJUVANT THERAPY; COHORT ANALYSIS; DRUG RESPONSE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUSCLE INVASIVE BLADDER CANCER; NEXT GENERATION SEQUENCING; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; TRANSURETHRAL RESECTION; ADJUVANT CHEMOTHERAPY; ADULT; AGED; CANCER STAGING; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS;

ADULT; AGED; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84921676709     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.01.014     Document Type: Article

References (8)

1. H.B. Grossman, R.B. Natale, C.M. Tangen, and et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
2. G. Sonpavde, B.H. Goldman, V.O. Speights, and et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy Cancer 115 2009 4104 4109
3. R.P. Meijer, J.A. Nieuwenhuijzen, W. Meinhardt, and et al. Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience Eur J Surg Oncol 39 2013 365 371
4. H. Greulich, B. Kaplan, P. Mertins, and et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 Proc Natl Acad Sci U S A 109 2012 14476 14481
5. R. Bose, S.M. Kavuri, A.C. Searleman, and et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer Cancer Discov 3 2013 224 237
6. J.S. Ross, K. Wang, L.M. Gay, and et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma Clin Cancer Res 20 2014 68 75
7. E.M. Van Allen, K.W. Mouw, P. Kim, and et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma Cancer Discov 4 2014 1140 1153
8. L.S. Mertens, R.P. Meijer, J.M. Kerst, and et al. Carboplatin based induction chemotherapy for nonorgan confined bladder cancer-a reasonable alternative for cisplatin unfit patients? J Urol 188 2012 1108 1113